Why this peptide is on people's radar
The Melanotan I / Scenesse story is one of the cleaner drug-development success stories in the melanocortin space. Erythropoietic protoporphyria (EPP) is a rare genetic disease, about 1 in 75,000 to 200,000 people, where defective heme synthesis causes accumulation of protoporphyrin IX in red blood cells. When affected people are exposed to light, the protoporphyrin IX absorbs energy and causes severe burning, swelling, and pain in the skin, often within minutes. Sunlight, even through windows, can be debilitating. Before Scenesse, the only management was strict avoidance of light.
Scenesse activates the MC1R receptor on melanocytes, increasing the conversion of pheomelanin to eumelanin, the darker form of melanin that absorbs light more effectively. The result is increased photoprotection. EPP patients on Scenesse can spend more time in light and reduce phototoxic episodes. The drug was approved by the EMA in 2014 and the FDA in 2019, after a long Australian-led development program.
The off-label / research-peptide tan story is mostly about Melanotan II rather than Melanotan I. Melanotan II is a different molecule (a more selective MC1R agonist, but with broader off-target activity at other melanocortin receptors), and has documented safety issues including melanoma changes and priapism. We have a separate page for Melanotan II in our Tier 4 compliance-sensitive review. The Scenesse / Melanotan I story is genuinely separate and shouldn't be conflated.
What people are usually trying to do with it
Almost exclusively the FDA-approved use:
- Reducing phototoxic episodes in adults with erythropoietic protoporphyria (EPP)
- Increasing time in light for EPP patients
- Improving quality of life in EPP, a very rare but profoundly limiting disease
- Following melanocortin pharmacology for academic interest
What the science actually shows
Plain-English summary:
EPP photoprotection (FDA-approved use)
Phase 3 trials showed Scenesse increased pain-free sun exposure time and reduced phototoxic episodes in EPP patients. Basis of the FDA approval.
Pigmentation effect
MC1R activation increases eumelanin production in melanocytes, producing visible skin darkening across body regions. The pigmentation is the protective mechanism, not the goal.
Selectivity vs Melanotan II
Afamelanotide is more selective for MC1R than Melanotan II is. Melanotan II also activates MC3R and MC4R, which is the basis of Melanotan II's off-target effects (appetite, sexual response, cardiovascular).
What hasn't been demonstrated
Approved tanning use. The drug's approved indication is photoprotection in a rare disease, not cosmetic tanning. Safety in long-term cosmetic-frequency use is uncharacterized, the approved protocol is bimonthly clinic implants in EPP patients.
The honest read
What's solid:
Scenesse is a real, fully-approved drug with rigorous Phase 3 evidence behind a meaningful indication. EPP patients have a meaningful quality-of-life option they didn't have before. Australia-based Clinuvel did the long development work to bring this through.
What's still being worked out:
Whether afamelanotide has utility in other photoprotection conditions (vitiligo, polymorphic light eruption, skin disorders involving photosensitivity). Clinuvel has explored these indications.
What's hyped beyond the evidence:
Treating Scenesse and Melanotan I generally as a cosmetic tanning option. The approved indication is photoprotection in a rare painful disease. The implant is administered bimonthly by a physician, costs thousands per implant, and is genuinely indicated only for EPP. Conflation with Melanotan II's research-peptide tan use case is a distinct mistake.
Things to know if you're looking into it
- FDA-approved indication: erythropoietic protoporphyria in adults. Not approved for cosmetic tanning.
- How it's administered: a small bioabsorbable implant placed subcutaneously by a physician every two months. Not self-injected.
- Don't confuse with Melanotan II: different molecule, different selectivity profile, different regulatory and safety status. Melanotan II's research-peptide tanning use has documented safety concerns; Melanotan I's approved use is for a rare disease.
- Common side effects from Scenesse Phase 3: nausea (especially with first treatments), facial flushing, fatigue, headache.
- Healthcare provider involvement: required. Scenesse is administered exclusively in clinic by trained physicians.
- Specific dosing protocols, mechanism, and the full reference list: all in the "Want to go deeper?" section below.
What people often ask
Is this the tanning peptide?
No. The tanning-peptide story usually refers to Melanotan II, a different molecule with broader receptor activity and documented safety concerns. Scenesse / Melanotan I is FDA-approved for a rare painful photosensitivity disease and is not used or approved for cosmetic tanning.
Is Scenesse FDA-approved?
Yes, for adults with erythropoietic protoporphyria. Approved 2019 by the FDA, earlier in the EU.
How is it different from Melanotan II?
Melanotan I (afamelanotide) is more selective for the MC1R receptor that drives skin pigmentation. Melanotan II also strongly activates MC3R and MC4R, which are involved in appetite, sexual response, and cardiovascular function, the basis of Melanotan II's reported side effects.
Does it work for vitiligo?
Has been studied off-label for vitiligo and other pigmentation disorders. Clinical evidence is limited and not the basis of the FDA approval.
What does an EPP treatment look like?
A small implant the size of a rice grain is inserted subcutaneously by a physician. The implant slowly releases afamelanotide over about two months, then dissolves. Patients typically receive three implants per year, timed to high-light seasons.
FDA and regulatory status
Status as of May 5, 2026: FDA-approved as Scenesse (October 2019) for adults with erythropoietic protoporphyria. Approved by the EMA in 2014 for the same indication. Manufactured by Clinuvel Pharmaceuticals. Status updates land here when they happen.
Want to go deeper?
Mechanism, the Phase 3 program, dosing, and references.
Background
Afamelanotide is a 13-amino-acid synthetic analog of α-melanocyte-stimulating hormone (α-MSH) with substitutions that confer enhanced potency and metabolic stability versus native α-MSH. Developed by Clinuvel Pharmaceuticals over multi-decade clinical development. EMA approval 2014, FDA approval October 2019.
Mechanism of action
Afamelanotide is a selective MC1R agonist. MC1R activation on melanocytes increases tyrosinase activity and shifts the melanin synthesis pathway toward eumelanin (the darker, more photoprotective form). The increased eumelanin in skin provides better absorption of light energy, reducing phototoxic damage in EPP.
FDA-approved dosing
16 mg subcutaneous implant placed by a healthcare professional every 2 months during periods of light exposure. Implant slowly releases over ~60 days, then bioabsorbs.
References
- Langendonk JG, Balwani M, Anderson KE, et al. (2015). "Afamelanotide for erythropoietic protoporphyria." N Engl J Med, 373(1), 48–59. PubMed
- Lim HW, Grimes PE, Agbai O, et al. (2015). "Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial." JAMA Dermatol, 151(1), 42–50. PubMed
- Hadley ME, Dorr RT. (2006). "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization." Peptides, 27(4), 921–930. PubMed
- U.S. Food and Drug Administration. "Scenesse Prescribing Information." FDA.gov